EUVIMEDEUVIMED entdecken
Editorial

Therapeutic drug monitoring—Does it really matter?

Hans Lennernäs iD, Jack Cook, Dennis A Hesselink iD

British Journal of Clinical Pharmacology · 2025-06 · 91 (6) · 1527-1529

DOI: 10.1111/bcp.16387 ↗

Kurz gefasst

Editorial in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 30.12.2024. Verfasst von Hans Lennernäs und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Bioscience, Drug Discovery and Development, Uppsala University, Uppsala, Sweden. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: HL is funded through grants obtained from the Swedish Cancer Foundation (Cancerfonden).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Department of Pharmaceutical Bioscience, Drug Discovery and Development, Uppsala University, Uppsala, Sweden.
  • A2-Ai LLC, Ann Arbor, Michigan, USA.
  • Erasmus MC Transplant Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.

ORCID-Profile: Hans Lennernäs, Dennis A Hesselink

Förderung

  • HL is funded through grants obtained from the Swedish Cancer Foundation (Cancerfonden)

Zitieren

APA

Lennernäs, H., Cook, J., & Hesselink, D. A. (2025). Therapeutic drug monitoring—Does it really matter?. British Journal of Clinical Pharmacology, 91(6), 1527-1529. https://doi.org/10.1111/bcp.16387

Vancouver

Lennernäs H, Cook J, Hesselink DA. Therapeutic drug monitoring—Does it really matter?. British Journal of Clinical Pharmacology. 2025;91(6):1527-1529. doi:10.1111/bcp.16387

BibTeX
@article{Lennerns2025,
  author = {Lennernäs, Hans and Cook, Jack and Hesselink, Dennis A},
  title = {Therapeutic drug monitoring—Does it really matter?},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  volume = {91},
  number = {6},
  pages = {1527--1529},
  doi = {10.1111/bcp.16387}
}
Kostenlos starten →